Track topics on Twitter Track topics that are important to you
Almac Diagnostic Services Ltd Almac Diagnostic Services, a subsidiary of Almac Group Ltd, is a medical diagnostic company that discovers, develops and commercializes diagnostic tests including companion diagnostics. The company provides products pipeline such as ColDx, DDRD, AADx, prostate Dx and MEK Dx, among others. It offers ColDx, a prognostic assay for stage II and III colon cancer, and DDRD, is a predictive assay for immuneoncology and DNA damaging agent. Almac Diagnostic Services provides preclinical biomarker discovery to companion diagnostic development including regulatory submissions and commercialization. The company provides applications such as patient selection, and are utilised in phase I to phase III registrational clinical trials. It operates laboratories in the US and the UK. Almac Diagnostic Services is headquartered in Craigavon, the UK.
This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Almac Diagnostic Services Ltd
The report provides pipeline analysis on all pipeline products of the company by equipment type, by indication, by development stage, and by trial status
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indications, applications and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials wherever applicable with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research Development strategies
Develop marketentry and market expansion strategies
Exploit inlicensing and outlicensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next highvalue products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the companyNEXT ARTICLE
Benign Prostatic Hyperplasia (BPH)
An enlarged prostate (benign prostatic enlargement (BPE) or benign prostatic hyperplasia (BPH)) is common in men after the age of about 50. Having an enlarged prostate does not mean you have cancer. In some cases, an enlarged prostate can cause the ...
An assay is an analytic procedure for qualitatively assessing or quantitatively measuring the presence or amount or the functional activity of a target entity. This can be a drug or biochemical substance or a cell in an organism or organic sample. ...
Colon or Colorectal cancer is the growth of malignant polyps on the colon, bowel, anus and rectum. Growths in these locations can be benign, and removed by colonoscopy, but they have a risk of becoming malignant. About 10 per cent of bowel cancer...